Literature DB >> 11284994

Chronic polyneuropathies in Vest-Agder, Norway.

A Mygland 1, P Monstad.   

Abstract

Epidemiological data on chronic polyneuropathies, especially inflammatory types, is limited. The purpose of this study was to examine the spectrum of causes and estimated prevalence of various polyneuropathy types in Vest-Agder, and to examine the clinical features of the Vest-Agder population of chronic inflammatory demyelinating polyneuropathy (CIDP). In Vest-Agder county (population of 155 464), polyneuropathy patients are registered in a database and followed prospectively. We did a measure of the database on October 31 1999. A total of 192 patients were registered. The prevalence for chronic inflammatory demyelinating polyneuropathy (CIDP) was 7.7 per 100 000 population. The course was relapsing in five of fifteen patients, progressive in four patients and slowly progressive in six of fifteen patients. Two of the fifteen patients had pure sensory symptoms. The mean Rankin disability score was 3.4 at maximal deficit and 2.1 at last follow-up. The prevalence of paraproteinemic polyneuropathy was 5.1 per 100 000 population. None of the patients with paraproteinemic polyneuropathy were worse than slightly disabled (disability score < or = 2). The prevalences for other polyneuropathies were as follows: polyneuropathy and RA, 1.3; polyneuropathy and Sjögren's syndrome or sicca complex, 4.5 (polyneuropathy was the presenting symptom in five of seven patients); sarcoidosis 1.9; polyneuropathy and chronic Lyme, 0.6; paraneoplastic polyneuropathy, 1.9; diabetic polyneuropathy 23.2; vitamin deficiency, 5.1; alcoholic and toxic polyneuropathy, 19.9; hereditary polyneuropathy, 14.8. Cryptogenic polyneuropathies made up 26% of all polyneuropathies. The mean disability score was 2.0 (SD 1.1). In conclusion, prevalence of CIDP was significantly higher than previously reported, and the prognosis was good in the majority of patients. Patients with paraproteinemic polyneuropathy were not severely disabled. Polyneuropathy was the presenting symptom in the majority of patients with Sjögren's syndrome or sicca complex.

Entities:  

Mesh:

Year:  2001        PMID: 11284994     DOI: 10.1046/j.1468-1331.2001.00187.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  30 in total

1.  The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).

Authors:  P Chérin; C Rose; C de Roux-Serratrice; D Tardy; D Dobbelaere; B Grosbois; E Hachulla; R Jaussaud; R-M Javier; E Noël; P Clerson; A Hartmann
Journal:  J Inherit Metab Dis       Date:  2010-06-02       Impact factor: 4.982

2.  Restless leg syndrome in different types of demyelinating neuropathies: a single-center pilot study.

Authors:  Marco Luigetti; Alessandra Del Grande; Elisa Testani; Giulia Bisogni; Anna Losurdo; Nadia Mariagrazia Giannantoni; Salvatore Mazza; Mario Sabatelli; Giacomo Della Marca
Journal:  J Clin Sleep Med       Date:  2013-09-15       Impact factor: 4.062

3.  Incidence of paraneoplastic polyneuropathies associated with non-Hodgkin lymphoma in the province of Asti, Italy.

Authors:  Gianluca Isoardo; Elisabetta Campa; Giuseppe Migliaretti; Walter Troni
Journal:  J Neurol       Date:  2007-01-27       Impact factor: 4.849

4.  The meaning of distal sensory loss and absent ankle reflexes in relation to age: a meta-analysis.

Authors:  Alexander F J E Vrancken; Sandra Kalmijn; Frans Brugman; Gabriël J E Rinkel; Nicolette C Notermans
Journal:  J Neurol       Date:  2005-11-23       Impact factor: 4.849

5.  Incidence and prevalence of CIDP and the association of diabetes mellitus.

Authors:  R S Laughlin; P J Dyck; L J Melton; C Leibson; J Ransom; P J B Dyck
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

Review 6.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 7.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

Review 8.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

9.  Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.

Authors:  Carlo Lazzaro; Leonardo Lopiano; Dario Cocito
Journal:  Neurol Sci       Date:  2014-01-28       Impact factor: 3.307

10.  Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy.

Authors:  A Chiò; D Cocito; E Bottacchi; C Buffa; M Leone; F Plano; R Mutani; A Calvo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.